GSK and Sun Pharma complete Opiates transaction

GlaxoSmithKline (GSK) and Sun Pharma have successfully completed the transfer of GSK’s Australian Opiates business that was acquired by Sun Pharma, effective 1 September. 

Geoff McDonald, General Manager, GSK Australia Pharmaceuticals said: “The Opiates business has been a valuable division of our Australian operations for many years. Completing this transaction enables GSK Australia to focus on the development of its innovative medicine and vaccine portfolio and the delivery of its Australian growth strategy. We thank our Opiates employees for their contribution to GSK and wish them every success with Sun Pharma.”

Andrew Holford, SVP Finance, GSK Global Manufacturing and Supply said: “We thank the teams at Port Fairy and Latrobe for everything they have done to build a sustainable and successful business over the years.  I’m sure there are many, many patients across the globe who have benefited from the innovations and commitment to quality that the site and business have demonstrated.”

 

Enquiries:

Bernadette Murdoch, Communications Director Australasia  Phone: 0449 950 745

 

Additional notes

GlaxoSmithKline - is a global research-based pharmaceutical and healthcare company. Since 1886 we have delivered the highest quality medicines, vaccines and over-the-counter healthcare products to Australians while investing in local research and providing skilled jobs. For further information please visit www.au.gsk.com.

GSK has two manufacturing facilities in Australia. Pharmaceutical products are manufactured in Boronia on the outskirts of Melbourne. It is one of GSK’s largest sterile facilities globally and includes two Relenza lines and innovative blow-fill-seal technology.

The GSK site at Ermington, in north-western Sydney, manufactures consumer products.